Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acinetobacter Baumannii (A. baumannii)
100%
Aminoglycosides
40%
Antibiotic Class
20%
Antibiotic Use
20%
Antibiotics
100%
Antibiotics Profile
20%
Antimicrobial
20%
Antimicrobial Resistance
40%
Antimicrobial Use Density
20%
Baumannii
20%
Carbapenem Use
20%
Carbapenem-resistant Acinetobacter Baumannii
40%
Carbapenems
40%
Clinical Laboratory
20%
Clonality
20%
Europe
20%
Fluoroquinolones
40%
Glycopeptides
40%
Incidence Density
20%
Increasing Trends
20%
Infection Control
20%
Infection Control Policies
20%
Infection Control Practices
20%
Intensive Care Unit
100%
Interhospital
20%
Intrahospital
20%
Klebsiella Pneumoniae (K. pneumoniae)
100%
Klebsiella Pneumoniae Carbapenemase
20%
Linear Regression
20%
Microorganism Control
20%
Microorganisms
20%
Multidrug-resistant Microorganisms
20%
Penicillin
40%
Pharmacy
20%
Resistance Profile
20%
Resistance Rate
60%
Resistant Infection
20%
Resistant Isolate
20%
Southern Italy
100%
Third-generation Cephalosporins
20%
Trends over Time
20%
Medicine and Dentistry
Acinetobacter Baumannii
100%
Aminoglycoside
50%
Antibiotic Resistance
50%
Antibiotics
25%
Antiinfective Agent
25%
Carbapenem
100%
Carbapenem Derivative
50%
Clonal Variation
25%
Glycopeptide
50%
Infection Control
50%
Intensive Care Unit
100%
Klebsiella pneumoniae
100%
Linear Regression Analysis
25%
Penicillin Derivative
50%
Quinolone Derivative
50%
Third Generation Cephalosporin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
100%
Aminoglycoside
50%
Antibiotic Resistance
50%
Antibiotics
25%
Antiinfective Agent
25%
Antimicrobial Resistance
50%
Carbapenem
100%
Carbapenem Derivative
50%
Glycopeptide
50%
Infection
50%
Klebsiella pneumoniae
100%
Microorganism
50%
Penicillin Derivative
50%
Quinolone Derivative
50%
Third Generation Cephalosporin
25%